Granted Patent B2

US 12,201,283 · App. 18/181,857 · Granted Jan 21, 2025

Inventors: Theodore Charles Lamson (Pleasanton, CA); Joshua Makower (Los Altos Hills, CA); Joseph Catanese, III (Oakland, CA); Jacqueline Nerney Welch (Moraga, CA); Amrish Jayprakash Walke (Santa Clara, CA); Claude Vidal (Santa Barbara, CA); Russell J. Redmond (Goleta, CA); Michael Collinson (Goleta, CA)

Assignee: Teleflex Life Sciences LLC

A61B17/00234A61B17/0482A61B17/06109A61B2017/00022A61B2017/00274A61B2017/00792A61B2017/00796A61B2017/00805A61B17/0218A61B17/0401A61B2017/0404A61B2017/0409A61B2017/0417A61B2017/0419A61B2017/0451A61B2017/0454A61B2017/0456A61B2017/0458A61B2017/0462A61B2017/0464A61B17/0467A61B17/0469A61B17/0487A61B2017/0488A61B2017/06052A61B2017/06176A61B17/3468A61B17/3478A61B17/42A61B2018/00547A61F2002/041A61F2/82

Abstract

Claims (22)

1. A method for treating benign prostatic hyperplasia, comprising:

inserting an interventional device comprising a tubular elongate device coupled with a hollow needle defining a sharp distal tip longitudinally through a urethra of a subject until a distal portion of the tubular elongate device reaches a position within the urethra distal to a prostate gland;

positioning the distal portion of the tubular elongate device at a first target region and advancing the hollow needle from an opening in the distal portion of the tubular elongate device into a lateral lobe of the prostate gland at the first target region;

injecting a therapeutic agent from the distal portion of the needle into the lateral lobe at the first target region;

repositioning the distal portion of the tubular elongate device at a second target region and advancing the hollow needle from the opening in the distal portion of the tubular elongate device into the lateral lobe at the second target region;

injecting more of the therapeutic agent from the distal portion of the needle into the lateral lobe at the second target region, wherein the therapeutic agent causes the lateral lobe to decrease in size; and

viewing a position of the interventional device using an endoscopic device advanced to the prostatic urethra.

2. The method of claim 1 , wherein the therapeutic agent causes the lateral lobe to decrease in size by forming a coagulative lesion in the lateral lobe that is subsequently resorbed.

3. The method of claim 2 , wherein the therapeutic agent comprises heat energy.

4. The method of claim 3 , wherein the heat energy comprises radiofrequency energy.

5. The method of claim 1 , wherein the therapeutic agent comprises a substance that dissolves, degrades, cuts, breaks, weakens, softens, modifiers, or remodels the lateral lobe.

6. The method of claim 1 , wherein inserting the interventional device longitudinally through the urethra of the subject comprises advancing a distal end of the tubular elongate device into the urinary bladder.

7. The method of claim 1 , further comprising introducing lidocaine to the urethra.

8. The method of claim 1 , wherein the endoscopic device comprises a cystoscope.

9. The method of claim 1 , wherein the interventional device comprises one or more side ports for introducing or removing one or more fluids.

10. The method of claim 1 , wherein the needle comprises stainless steel, a nickel-titanium alloy, titanium, or combinations thereof.

11. The method of claim 1 , wherein viewing the position of the interventional device comprises detecting a position of one or more radiopaque markers positioned on the interventional device.

12. The method of claim 11 , wherein the one or more radiopaque markers comprise a distal marker band and a proximal marker band.

13. The method of claim 12 , further comprising confirming that the distal marker band is positioned within the lateral lobe before injecting the therapeutic agent into the lateral lobe.

14. The method of claim 1 , wherein the endoscopic device is inserted through the tubular elongate device.

15. The method of claim 1 , wherein the tubular elongate device comprises an introducing sheath comprising stainless steel, nickel-titanium alloy, titanium, or combinations thereof.

16. The method of claim 1 , wherein the tubular elongate device comprises an introducing sheath comprising Pebax, polyimide, nylon, PVC, Hytrel, HDPE, PEEK, PTFE, PFA, FEP, EPTFE, or combinations thereof.

Assignments (7)

Continuity (8)

References Cited (400)